[Nature Communications] Scientists discerned that the effect of α-lipoic acid on mitigating intestinal stem cell (ISC) aging is contingent upon the presence of Paneth cells.

[Advanced Science] Investigators revealed the mechanism of mitochondrial carrier homolog 2 (MTCH2) deficiency-induced ferroptosis to inhibit the progression of colorectal cancer.

[Nature Communications] Researchers performed genomics analyses of twenty gastric squamous cell carcinoma samples and found that epigenetic regulation genes are among the most frequently mutated genes, including enhancer of zeste homolog 2 (EZH2).

[Molecular Cancer] Scientists revealed a novel circERC1 as a key regulator in pancreatic ductal adenocarcinoma-secreted EVs following paclitaxel treatment, thereby inhibiting gemcitabine/Nab-paclitaxel induced pyroptosis.

[CytoDyn, Inc.] CytoDyn, Inc. announced that the first patient has been dosed in the Company’s clinical trial evaluating the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer.

[Molecular Cancer] The authors explored the upregulation pattern and molecular mechanisms of serine/threonine kinase 3 (STK3) in advancing gastric cancer progression.

[Cellular & Molecular Immunology] Owing to significant interspecies differences in liver immunology, human models, such as classical cocultures or organogenesis-inspired liver organoids with immune compartments, are becoming essential for advancing the field.

[Science Translational Medicine] Emerging RNA interference therapies targeting hepatitis B virus RNAs reduce viral replication, antigen expression, and, in turn, cccDNA activity, providing a potential path to a functional cure.

[Cell Research] Scientists established a chemically defined patient-derived organoid system that enables long-term expansion of colorectal cancer cells while preserving fetal-like features associated with phenotypic plasticity.

[Science] Investigators established FOXA1 as a multifaceted oncogene, with distinct mutational classes divergently evolving to drive prostate tumorigenesis or therapy-resistant progression.

[Nature Cancer] Researchers showed that Pten deletion in basal cells led to distinct cell fate reprogramming and tumor initiation in a regionalized manner.

[Molecular Cell] Scientists demonstrated that dysregulated ubiquitination and turnover by the cullin 3^ZBTB2 E3 ligase complex induce the upregulation of the short isoform of nuclear-receptor-binding SET domain protein 3, which confers PARPi resistance in prostate cancer cells and patient-derivedmetastatic castration-resistant prostate cancer samples.